Deep Brain Stimulation in Parkinson's Disease

Deep brain stimulation (DBS) is the most established and evidence-based surgical therapy for Parkinson's disease. Since its approval in the late 1990s, DBS has evolved from a last-resort intervention for severely disabled patients to a well-timed therapeutic option for patients with early motor complications. This article provides a comprehensive review of DBS candidacy, surgical technique, target selection (STN vs GPi), programming principles, outcomes from landmark trials, complications, and emerging technologies including adaptive (closed-loop) DBS.

Patient Selection

Patient selection is the single most important determinant of DBS outcome. A well-selected patient with realistic expectations will have an excellent outcome; a poorly selected patient may be made worse.

Core candidacy criteria:

• Confirmed levodopa-responsive PD: ≥30% improvement in MDS-UPDRS III with levodopa challenge (some centers use ≥33%). The magnitude of levodopa response predicts the magnitude of DBS benefit for bradykinesia and rigidity
• Disabling motor complications despite optimized medical therapy — wearing off, dyskinesia, ON-OFF fluctuations that meaningfully impair quality of life
• No dementia: Mattis Dementia Rating Scale >130 (or equivalent screening). DBS does not improve cognition and may worsen it, particularly with STN
• No untreated/unstable psychiatric disease: Active psychosis, severe untreated depression, or active suicidality are exclusion criteria. Stable, treated psychiatric conditions are not absolute contraindications
• Medically fit for surgery: Appropriate cardiovascular risk, no coagulopathy, no significant brain atrophy or structural lesions on MRI
• Realistic expectations: Patient and caregiver understand what DBS can and cannot do

Exception — medication-refractory tremor: DBS (typically VIM thalamotomy or STN) can be highly effective for PD tremor that does not respond adequately to levodopa or other medications, even in the absence of motor fluctuations. Tremor is the one PD symptom where DBS benefit can exceed the levodopa response.

Surgical Technique

Preoperative planning:

• High-resolution MRI (typically 3T) for direct visualization of target nuclei (STN, GPi) and planning of electrode trajectory
• Stereotactic frame-based or frameless (robot-assisted) approaches are both used; no definitive evidence that one is superior
• Multidisciplinary team: movement disorder neurologist, functional neurosurgeon, neuropsychologist, psychiatrist, and DBS nurse specialist

Intraoperative:

• Awake surgery with microelectrode recording (MER): Traditional approach — patient is awake (off medications overnight), microelectrodes record single-neuron activity to confirm target, clinical testing confirms benefit and absence of side effects before permanent lead placement
• Asleep surgery (general anesthesia with intraoperative MRI/CT): Increasingly used, particularly for patients who cannot tolerate awake surgery. Intraoperative imaging confirms lead placement. Outcomes comparable to awake surgery in non-randomized comparisons
• Bilateral leads placed in the same session (most common) or staged procedures

Hardware:

• Leads: Quadripolar (4 contacts) or directional leads (segmented contacts allowing current steering in specific directions — newer technology enabling more precise targeting and fewer side effects)
• Pulse generator (IPG): Implanted subclavicularly. Non-rechargeable (replaced every 3–5 years) or rechargeable (lasts 15+ years). Rechargeable devices reduce reoperation burden
• MRI compatibility: Newer systems are conditionally MRI-compatible (specific conditions must be met); older systems may preclude MRI

Target Selection: STN vs GPi

The subthalamic nucleus (STN) and globus pallidus internus (GPi) are the two established DBS targets for PD. Four landmark RCTs inform this decision:

DBS Programming

Programming begins 2–4 weeks after surgery (allowing edema to resolve). The goal is to identify the optimal combination of active contacts, stimulation amplitude (voltage or current), pulse width, and frequency that maximizes motor benefit while minimizing side effects.

Key principles:

• Monopolar survey: Test each contact individually to identify the best therapeutic contact(s) — assess for tremor suppression, rigidity reduction, and side-effect thresholds (paresthesia, muscle contraction, speech impairment, gaze deviation)
• Standard initial parameters: Frequency 130 Hz (standard), pulse width 60–90 μsec, amplitude titrated from 1V upward
• Directional steering (with segmented leads): Allows current to be directed away from adjacent structures causing side effects (e.g., internal capsule → contraction, medial lemniscus → paresthesia) while maintaining therapeutic effect
• Medication adjustment: With STN-DBS, dopaminergic medications are typically reduced by 30–50% over the first months; with GPi-DBS, changes are more modest
• Chronic optimization: Multiple programming sessions over months are typically needed. Patients should be evaluated in both ON-stimulation and OFF-stimulation states

Common side effects addressable by programming:

• Dysarthria/speech impairment: The most common stimulation-related side effect. May improve with reduced amplitude, pulse width, or directional steering. Bilateral STN stimulation carries higher dysarthria risk
• Muscle contraction (capsular effect): Spread to internal capsule. Reduce amplitude or use directional steering
• Paresthesia: Spread to medial lemniscus. Usually transient; may require contact change
• Eyelid opening apraxia: Can occur with STN-DBS; often improves with contact or parameter adjustment
• Gait impairment: May require frequency adjustment (low-frequency stimulation at 60–80 Hz has been explored for gait/freezing)

Outcomes & Long-Term Results

DBS provides robust, sustained improvement in motor symptoms and quality of life, though benefit may attenuate over time as disease progresses:

• Short-term (6 months–2 years): UPDRS-III improvement of 25–50% in off-medication state; OFF time reduction of 4–6 hours/day; dyskinesia reduction of 60–80%; PDQ-39 improvement of 5–10 points
• Long-term (5–10+ years): Motor benefits partially sustained but attenuate, particularly for axial symptoms (gait, balance, speech). Tremor benefit tends to be the most durable. Medication doses typically increase over time as disease progresses. Quality of life may return to pre-surgical levels by 5–8 years due to ongoing neurodegeneration
• Non-motor symptoms: DBS may improve sleep (from reduced nocturnal OFF), pain (from better motor control), and mood (in selected patients). It does not improve cognition, autonomic function, or most NMS

Complications

Surgical complications:

• Intracranial hemorrhage: 1–3% per lead (symptomatic); most are small, asymptomatic; rarely devastating
• Infection: 3–5% (lead, extension, or IPG site); may require hardware explantation and IV antibiotics
• Lead malposition: 1–2%; may require lead revision surgery
• Pneumothorax: Rare (from IPG pocket creation)
• Perioperative mortality: <0.5%

Hardware complications:

• Lead fracture or migration: 2–5% over device lifetime; requires reoperation
• IPG malfunction: Rare with modern devices
• Battery depletion: Non-rechargeable IPGs require replacement every 3–5 years (minor surgical procedure)
• Skin erosion over hardware (especially thin patients)

Stimulation-related:

• Dysarthria, muscle contraction, paresthesia, gait disturbance, eyelid apraxia — usually addressable by programming
• Neuropsychiatric: Depression, apathy (especially with STN + rapid med reduction), hypomania/impulsivity (acute STN stimulation), weight gain (5–10 kg average post-STN)
• Suicide risk: Slightly elevated in post-DBS patients compared to medically treated controls (EARLYSTIM: 2 suicides in DBS group vs 1 in medical group). Mechanisms debated — rapid dopaminergic medication reduction, altered reward circuitry, loss of "fight" associated with active disease management. Close psychiatric follow-up is mandatory

Emerging Technologies

Adaptive (Closed-Loop) DBS

Conventional DBS delivers continuous, open-loop stimulation regardless of the patient's real-time motor state. Adaptive DBS (aDBS) uses neural biomarkers — primarily beta-frequency (13–30 Hz) oscillatory activity recorded from the STN — to modulate stimulation in real time. When beta power is high (correlating with bradykinesia/rigidity), stimulation increases; when beta power normalizes (ON state), stimulation decreases. Early clinical studies show aDBS provides equivalent or superior motor benefit with ~50% less total energy delivered, potentially reducing side effects (especially speech) and extending battery life. The Medtronic Percept PC and newer Boston Scientific devices can record local field potentials, enabling the first steps toward clinical aDBS implementation.

Directional Leads

Segmented (directional) leads divide some contacts into 3 directional segments, allowing the current field to be steered toward the therapeutic target and away from structures causing side effects. This effectively enlarges the therapeutic window and has shown improved side-effect profiles in clinical studies, particularly for capsular effects and speech impairment.

Other DBS Targets Under Investigation

• Pedunculopontine nucleus (PPN): Under investigation for freezing of gait and postural instability (symptoms not improved by STN/GPi). Results from small trials have been mixed
• Zona incerta / caudal zona incerta: Some evidence for tremor control superior to VIM; under investigation
• Combined targets: STN + PPN or STN + GPi for patients with both fluctuations and axial symptoms; limited evidence

Trial Comparison Table